A Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of Adalimumab (TUR01 and EU Sourced Humira®) in Healthy Subjects
Latest Information Update: 26 Jun 2020
At a glance
- Drugs Adalimumab (Primary)
- Indications Autoimmune disorders
- Focus Pharmacokinetics
- Sponsors Turgut Ilac
Most Recent Events
- 26 Jun 2020 New trial record